Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CLOPIDOGREL BISULFATE

16 general benefit · 3 not a benefit

Other products in the same Health Canada class (B01AC) — coverage varies; not interchangeable

  • Ticlopidine (Ticlid): limited Use 219, 220, 221, Not a benefit

Apo-Clopidogrel · DIN 02252767 · 75mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Apo-Clopidogrel · DIN 02252767 Manufacturer: Apotex Inc.; listing date 2012-01-19 Health Canada: Marketed since 2011-12-19 · brand APO-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Apo-Clopidogrel: Formulary list price $0.2631/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2631 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73770 · Verify on the e-Formulary ↗ (DIN 02252767)

Source record
DIN 02252767: Apo-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2167; lccId None; manufacturer id APX Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02252767 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=73770
Interchangeable products
Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended 2026-01-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02252767
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Auro-Clopidogrel · DIN 02416387 · 75mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Auro-Clopidogrel · DIN 02416387 Manufacturer: Auro Pharma Inc.; listing date 2014-04-30 Health Canada: Marketed since 2014-02-06 · brand AURO-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Auro pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

Auro-Clopidogrel: Formulary list price $0.2631/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2631 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90094 · Verify on the e-Formulary ↗ (DIN 02416387)

Source record
DIN 02416387: Auro-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2167; lccId None; manufacturer id AUR Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02416387 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90094
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended 2024-09-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02416387
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Bio-Clopidogrel · DIN 02444895 · 75mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Bio-Clopidogrel · DIN 02444895 Manufacturer: Biomed Pharma; listing date 2026-07-31 Health Canada: Marketed since 2023-08-02 · brand BIO-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Biomed pharma · schedule Prescription
Check this DIN again · Health Canada product record

Bio-Clopidogrel: Formulary list price $0.2631/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2631 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93012 · Verify on the e-Formulary ↗ (DIN 02444895)

Source record
DIN 02444895: Bio-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2167; lccId None; manufacturer id BMP Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02444895 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93012
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02444895
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Clopidogrel · DIN 02385813 · 75mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Clopidogrel · DIN 02385813 Manufacturer: Sivem Pharmaceuticals ULC; listing date 2020-06-30 Health Canada: Marketed since 2012-06-11 · brand CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Sivem pharmaceuticals ulc · schedule Prescription
Check this DIN again · Health Canada product record

Clopidogrel: Formulary list price $0.2631/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2631 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87143 · Verify on the e-Formulary ↗ (DIN 02385813)

Source record
DIN 02385813: Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2167; lccId None; manufacturer id SIV Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02385813 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87143
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended 2021-04-09); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02385813
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Clopidogrel · DIN 02400553 · 75mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Clopidogrel · DIN 02400553 Manufacturer: Sanis Health Inc.; listing date 2020-06-30 Health Canada: Marketed since 2021-05-14 · brand CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Sanis health inc · schedule Prescription
Check this DIN again · Health Canada product record

Clopidogrel: Formulary list price $0.2631/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2631 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88535 · Verify on the e-Formulary ↗ (DIN 02400553)

Source record
DIN 02400553: Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2167; lccId None; manufacturer id SAI Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02400553 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88535
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended 2026-02-02); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02400553
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Jamp-Clopidogrel · DIN 02415550 · 75mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Jamp-Clopidogrel · DIN 02415550 Manufacturer: Jamp Pharma Corporation; listing date 2014-07-30 Health Canada: Marketed since 2014-01-15 · brand JAMP-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Jamp pharma corporation · schedule Prescription
Check this DIN again · Health Canada product record

Jamp-Clopidogrel: Formulary list price $0.2631/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2631 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90014 · Verify on the e-Formulary ↗ (DIN 02415550)

Source record
DIN 02415550: Jamp-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2167; lccId None; manufacturer id JPC Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02415550 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90014
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended 2025-08-18); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02415550
Shortage record checked 2026-09-13T08:10:21.292534+00:00

M-Clopidogrel · DIN 02502283 · 75mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
M-Clopidogrel · DIN 02502283 Manufacturer: Mantra Pharma Inc.; listing date 2021-11-30 Health Canada: Marketed since 2020-11-03 · brand M-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Mantra pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

M-Clopidogrel: Formulary list price $0.2631/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2631 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99186 · Verify on the e-Formulary ↗ (DIN 02502283)

Source record
DIN 02502283: M-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2167; lccId None; manufacturer id MAT Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02502283 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99186
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended 2026-02-10); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02502283
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mar-Clopidogrel · DIN 02422255 · 75mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mar-Clopidogrel · DIN 02422255 Manufacturer: Marcan Pharmaceuticals Inc.; listing date 2014-06-26 Health Canada: Marketed since 2023-06-14 · brand MAR-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Marcan pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mar-Clopidogrel: Formulary list price $0.2631/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2631 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90695 · Verify on the e-Formulary ↗ (DIN 02422255)

Source record
DIN 02422255: Mar-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2167; lccId None; manufacturer id MAR Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02422255 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90695
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended 2021-04-13); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02422255
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Mint-Clopidogrel · DIN 02408910 · 75mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Mint-Clopidogrel · DIN 02408910 Manufacturer: Mint Pharmaceuticals Inc.; listing date 2013-09-27 Health Canada: Marketed since 2023-03-29 · brand MINT-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Mint pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Mint-Clopidogrel: Formulary list price $0.2631/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2631 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89366 · Verify on the e-Formulary ↗ (DIN 02408910)

Source record
DIN 02408910: Mint-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2167; lccId None; manufacturer id MIN Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02408910 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=89366
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended 2019-04-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02408910
Shortage record checked 2026-09-13T08:10:21.292534+00:00

NRA-Clopidogrel · DIN 02482037 · 75mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
NRA-Clopidogrel · DIN 02482037 Manufacturer: Nora Pharma; listing date 2020-06-30 Health Canada: Marketed since 2020-03-05 · brand NRA-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Nora pharma inc · schedule Prescription
Check this DIN again · Health Canada product record

NRA-Clopidogrel: Formulary list price $0.2631/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2631 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97237 · Verify on the e-Formulary ↗ (DIN 02482037)

Source record
DIN 02482037: NRA-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2167; lccId None; manufacturer id NRA Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02482037 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=97237
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02482037
Shortage record checked 2026-09-13T08:10:21.292534+00:00

PMS-Clopidogrel · DIN 02348004 · 75mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Clopidogrel · DIN 02348004 Manufacturer: Pharmascience Inc.; listing date 2012-02-29 Health Canada: Marketed since 2011-12-14 · brand PMS-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Pharmascience inc · schedule Prescription
Check this DIN again · Health Canada product record

PMS-Clopidogrel: Formulary list price $0.2631/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2631 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83336 · Verify on the e-Formulary ↗ (DIN 02348004)

Source record
DIN 02348004: PMS-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2167; lccId None; manufacturer id PMS Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02348004 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=83336
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended 2018-10-01); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02348004
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Plavix · DIN 02238682 · 75mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists PLAVIX (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Plavix · DIN 02238682 Manufacturer: Sanofi Aventis Pharma; listing date 2003-09-04 Health Canada: Marketed since 2007-04-10 · brand PLAVIX · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Sanofi-aventis canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.2631 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62114 · Verify on the e-Formulary ↗ (DIN 02238682)

Source record
DIN 02238682: Plavix Raw flags: sec3=Y Item: 920000303; group id 906; item number 2167; lccId None; manufacturer id SAV Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $2.9350; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02238682 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=62114
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended 2023-12-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02238682
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Ran-Clopidogrel · DIN 02379813 · 75mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Ran-Clopidogrel · DIN 02379813 Manufacturer: Ranbaxy Pharmaceuticals Canada Inc.; listing date 2012-06-26 Health Canada: Marketed since 2020-06-26 · brand TARO-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Sun pharma canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Ran-Clopidogrel: Formulary list price $0.2631/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2631 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86568 · Verify on the e-Formulary ↗ (DIN 02379813)

Source record
DIN 02379813: Ran-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2167; lccId None; manufacturer id RAN Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02379813 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86568
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended 2024-05-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02379813
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Clopidogrel · DIN 02293161 · 75mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Teva-Clopidogrel · DIN 02293161 Manufacturer: Teva Canada Limited; listing date 2012-02-29 Health Canada: Marketed since 2011-12-14 · brand TEVA-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Teva-Clopidogrel: Formulary list price $0.2631/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2631 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77854 · Verify on the e-Formulary ↗ (DIN 02293161)

Source record
DIN 02293161: Teva-Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2167; lccId None; manufacturer id TEV Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02293161 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=77854
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631
Shortage status: shortage reported ended 2026-07-31 (report last updated 2026-07-31); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02293161
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Apo-Clopidogrel · DIN 02398591 · 300mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Apo-Clopidogrel · DIN 02398591 Manufacturer: Apotex Inc.; listing date 2013-06-27 Health Canada: Marketed since 2013-01-21 · brand APO-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 300 MG · company Apotex inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88354 · Verify on the e-Formulary ↗ (DIN 02398591)

Source record
DIN 02398591: Apo-Clopidogrel Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 920000663; group id 906; item number 2168; lccId None; manufacturer id APX Source form: Tab; strength: 300mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $9.5447; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02398591 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=88354
Interchangeable products
Plavix · DIN 02330555 · not recorded Teva-Clopidogrel · DIN 02388065 · not recorded
Shortage status: active shortage (reported 2026-09-01, estimated to end 2026-10-30, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02398591
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Teva-Clopidogrel · DIN 02388065 · 300mg · tablet

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Teva-Clopidogrel · DIN 02388065 Manufacturer: Teva Canada Limited; listing date 2012-08-27 Health Canada: Marketed since 2013-01-02 · brand TEVA-CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 300 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87363 · Verify on the e-Formulary ↗ (DIN 02388065)

Source record
DIN 02388065: Teva-Clopidogrel Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 920000663; group id 906; item number 2168; lccId None; manufacturer id TEV Source form: Tab; strength: 300mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $9.5447; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02388065 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=87363
Interchangeable products
Apo-Clopidogrel · DIN 02398591 · not recorded Plavix · DIN 02330555 · not recorded
Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02388065
Shortage record checked 2026-09-13T08:10:21.292534+00:00

Co Clopidogrel · DIN 02303027 · 75mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-29 — choose a marketed DIN from the same-category list.Discontinued 2025-04-29 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2025-04-29 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2025-04-29 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Co Clopidogrel · DIN 02303027 Manufacturer: Cobalt Pharmaceuticals Company; listing date 2012-01-19 Health Canada: Cancelled post market since 2025-04-29 · brand ACT CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Teva canada limited · schedule Prescription
Check this DIN again · Health Canada product record

Co Clopidogrel: Formulary list price $0.2631/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2631 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78834 · Verify on the e-Formulary ↗ (DIN 02303027)

Source record
DIN 02303027: Co Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2167; lccId None; manufacturer id COB Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02303027 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78834
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Sandoz Clopidogrel · DIN 02359316 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: discontinued (2018-02-28, reported by ACTAVIS PHARMA COMPANY); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02303027
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2025-04-29 — choose a marketed DIN from the same-category list.

Sandoz Clopidogrel · DIN 02359316 · 75mg · tablet

General benefit; Health Canada lists this DIN as Cancelled post market since 2021-06-28 — choose a marketed DIN from the same-category list.Discontinued 2021-06-28 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2021-06-28 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2021-06-28 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims: 6.2 Medically Necessary "No Substitution" Claims The Side Effect Reporting Form will not have to be renewed. However, the pharmacy must maintain a copy of the prescription that contains a direction that there be no substitution and the required Health Canada Side Effect Reporting Form (completed and signed by the prescriber). The prescriber must write “No Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will be reimbursed the DBP plus a mark-up and the lesser of the posted usual and customary fee or the ODB dispensing fee minus the applicable ODB co-payment amount. Where a completed Side Effect Reporting Form is not available at the pharmacy during an inspection, the difference between the cost of the higher-cost product and the lowest DBP listed for the interchangeable category will be recovered. (ontario.ca, Revision #17; 2026-08-03 ↗) 6.2 Medically Necessary "No Substitution" Claims The Ministry will provide reimbursement of a higher-cost interchangeable product in medically necessary circumstances where a patient has experienced a significant adverse reaction with two (2) lower-cost interchangeable drug products, where available. When a prescriber identifies a patient for which it is medically necessary that a higher cost interchangeable product be provided, the prescriber must: • Complete, sign and forward to the pharmacist a copy of the Health Canada side effect reporting form for each lower-cost interchangeable drug product trialed (Side Effect Reporting Form[s]); and • Write “No Substitution” or “No Sub” on a written prescription or indicate “No Substitution” to the pharmacist in the case of a verbal prescription. The prescriber should keep a copy of the completed form in the patient’s record for future use and reference. In the case of a written prescription, when the pharmacist or dispensing physician receives a prescription with the written notation “No Substitution” or “No Sub”, reimbursement will be provided for the higher-cost interchangeable product only if the prescription is accompanied by a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed. This form must be completely filled out noting the details of the adverse reaction and signed by the prescriber. In the case of a verbal prescription, the prescriber must satisfy the operator of the pharmacy or dispensing physician that a completed Health Canada Side Effect Reporting Form for each of the lower-cost interchangeable drug products trialed has been completed and signed by the prescriber. A written record of this verbal prescription and the completed Health Canada Side Effect Reporting Form must be received by the pharmacy prior to claim submission. Upon receipt, the pharmacist must: • Fax, submit online or mail the completed and signed form to Health Canada’s Canada Vigilance Program; and • Retain his or her copy of the completed and signed Side Effect Reporting Form. (ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Sandoz Clopidogrel · DIN 02359316 Manufacturer: Sandoz Canada Inc.; listing date 2012-02-29 Health Canada: Cancelled post market since 2021-06-28 · brand SANDOZ CLOPIDOGREL · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75 MG · company Sandoz canada incorporated · schedule Prescription
Check this DIN again · Health Canada product record

Sandoz Clopidogrel: Formulary list price $0.2631/unit (unit not stated in source; not the patient's cost)

Ministry pays: $0.2631 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84434 · Verify on the e-Formulary ↗ (DIN 02359316)

Source record
DIN 02359316: Sandoz Clopidogrel Raw flags: sec3=Y Item: 920000303; group id 906; item number 2167; lccId None; manufacturer id SDZ Source form: Tab; strength: 75mg Recorded listing: General benefit Source prices (unrounded): $0.2631; ministry $0.2631 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02359316 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84434
Interchangeable products
Apo-Clopidogrel · DIN 02252767 · $0.2631 Auro-Clopidogrel · DIN 02416387 · $0.2631 Bio-Clopidogrel · DIN 02444895 · $0.2631 Clopidogrel · DIN 02385813 · $0.2631 Clopidogrel · DIN 02400553 · $0.2631 Co Clopidogrel · DIN 02303027 · $0.2631 Jamp-Clopidogrel · DIN 02415550 · $0.2631 M-Clopidogrel · DIN 02502283 · $0.2631 Mar-Clopidogrel · DIN 02422255 · $0.2631 Mint-Clopidogrel · DIN 02408910 · $0.2631 NRA-Clopidogrel · DIN 02482037 · $0.2631 PMS-Clopidogrel · DIN 02348004 · $0.2631 Plavix · DIN 02238682 · $0.2631 Ran-Clopidogrel · DIN 02379813 · $0.2631 Teva-Clopidogrel · DIN 02293161 · $0.2631
Shortage status: resolved shortage (ended 2021-06-28); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02359316
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2021-06-28 — choose a marketed DIN from the same-category list.

Plavix · DIN 02330555 · 300mg · tablet

Off-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2020-12-10 — choose a marketed DIN from the same-category list.Discontinued 2020-12-10 · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit; Health Canada lists this DIN as Cancelled post market since 2020-12-10 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2020-12-10 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Savings card: RxHelp ONE lists PLAVIX (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Plavix · DIN 02330555 Manufacturer: Sanofi Aventis Pharma; listing date 2012-08-27 Health Canada: Cancelled post market since 2020-12-10 · brand PLAVIX · ATC B01AC04 CLOPIDOGREL · form Tablet · route Oral · ingredients CLOPIDOGREL (CLOPIDOGREL BISULFATE) 300 MG · company Sanofi-aventis canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Plavix: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81628 · Verify on the e-Formulary ↗ (DIN 02330555)

Source record
DIN 02330555: Plavix Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 920000663; group id 906; item number 2168; lccId None; manufacturer id SAV Source form: Tab; strength: 300mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02330555 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=81628
Interchangeable products
Apo-Clopidogrel · DIN 02398591 · not recorded Teva-Clopidogrel · DIN 02388065 · not recorded
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02330555
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2020-12-10 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (92:00 UNCLASSIFIED THERAPEUTIC AGENTS) and how they are covered

Matched class: 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ALENDRONATE & CHOLECALCIFEROL, AZATHIOPRINE, CYCLOSPORINE, GLUCAGON RDNA ORIGIN, LANREOTIDE ACETATE, LEFLUNOMIDE, LEVODOPA & BENSERAZIDE, MYCOPHENOLATE SODIUM Some products covered without a code (check the product listing): ALENDRONATE, ALLOPURINOL, AMANTADINE HCL, BROMOCRIPTINE, LEVODOPA & CARBIDOPA, MYCOPHENOLATE MOFETIL, OCTREOTIDE, RISEDRONATE SODIUM, ROPINIROLE, SELEGILINE HCL, TAMSULOSIN HCL 92:00 UNCLASSIFIED THERAPEUTIC AGENTS

TICLOPIDINE HCL

· 2 products · Listed, not a benefit (1), Limited Use, codes 219, 220, 221 (1) · strengths: 250mg · Tab

ALENDRONATE

· 28 products · Off-Formulary Interchangeable, not an ODB benefit (4), Listed, not a benefit (1), General benefit (23) · strengths: 5mg, 10mg, 70mg · Tab

ALENDRONATE & CHOLECALCIFEROL

· 6 products · General benefit · strengths: 70mg & 70mcg, 70mg & 140mcg · Tab

ALLOPURINOL

· 10 products · General benefit (6), Listed, not a benefit (4) · strengths: 100mg, 200mg, 300mg · Tab

AMANTADINE HCL

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 100mg, 10mg/mL · Cap, O/L

AZATHIOPRINE

· 3 products · General benefit · strengths: 50mg · Tab

BROMOCRIPTINE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 5mg, 2.5mg · Cap, Tab

CYCLOSPORINE

· 8 products · General benefit · strengths: 10mg, 25mg, 50mg, 100mg, 100mg/mL · Cap, O/L

GLUCAGON RDNA ORIGIN

· 2 products · General benefit · strengths: 1mg/Vial · Inj Pd-Syr Pk, Inj Pd-Vial Pk

LANREOTIDE ACETATE

· 6 products · General benefit · strengths: 60mg/Syr, 90mg/Syr, 120mg/Syr · ER Pref Syr Pk

LEFLUNOMIDE

· 16 products · General benefit · strengths: 10mg, 20mg · Tab

LEVODOPA & BENSERAZIDE

· 3 products · General benefit · strengths: 50mg & 12.5mg, 100mg & 25mg, 200mg & 50mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 92:00 and 75 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 INDICATIONS PLAVIX (clopidogrel bisulfate) is indicated: • for the secondary prevention of atherothrombotic events (myocardial infarction, stroke and vascular death) in patients with atherosclerosis documented by stroke, myocardial infarction, or established peripheral arterial disease. • in combination with acetylsalicylic acid (ASA), for the early and long-term secondary prevention of atherothrombotic events (myocardial infarction, ischemic stroke, cardiovascular death and/or refractory ischemia) in patients with acute coronary syndromes - without ST segment elevation (i.e., unstable angina or non-Q-wave myocardial infarction). These benefits of PLAVIX have been shown only when these patients were concomitantly treated with ASA in addition to other standard therapies. These benefits were also seen in patients who were managed medically and those who were managed with percutaneous coronary intervention (with or without stent) or CABG (coronary artery bypass graft). • For patients with ST-segment elevation acute myocardial infarction, PLAVIX has been shown to reduce the rate of an endpoint of all-cause m… https://pdf.hres.ca/dpd_pm/00067958.PDF PM date: OCT 07, 1998 Source product: PLAVIX; DIN 02238682; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Teva-Clopidogrel · DIN 02293161 Shortage status: shortage reported ended 2026-07-31 (report last updated 2026-07-31); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02293161

Check this DIN again

Apo-Clopidogrel · DIN 02398591 Shortage status: active shortage (reported 2026-09-01, estimated to end 2026-10-30, last updated 2026-09-04); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02398591

Check this DIN again

Teva-Clopidogrel · DIN 02388065 Shortage status: shortage reported ended 2026-05-05 (report last updated 2026-05-05); confirm supply with the pharmacy; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02388065

Check this DIN again

Co Clopidogrel · DIN 02303027 Shortage status: discontinued (2018-02-28, reported by ACTAVIS PHARMA COMPANY); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02303027

Check this DIN again

Plavix · DIN 02330555 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02330555

Check this DIN again

Other review policies

For Apo-Clopidogrel, Teva-Clopidogrel, Plavix: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026